Clik here to view.
J&J filing aims Tremfya at crowded psoriatic arthritis market
Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share. Tremfya...
View ArticleClik here to view.
FDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fall
The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread. Already on the market for patients in the early stages of the...
View ArticleClik here to view.
J&J gets okay for a third first-line Darzalex combo in US
Johnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting an FDA approval as an add-on to a widely-used triple-drug regimen....
View ArticleClik here to view.
J&J settles Ohio lawsuits for $20m as opioid litigation train rumbles on
Johnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, saying that will evert a federal trial that had been due to take place in Cleveland later...
View ArticleClik here to view.
J&J seeks wider use of its Spravato antidepressant in US
Johnson & Johnson has filed for US approval for a new claim on the label for its nasal spray antidepressant Spravato that would extend its use to include patients who are considered at high risk...
View ArticleClik here to view.
MSF calls for J&J to cut price of TB medicine
The humanitarian medical organisation Medecins Sans Frontieres (MSF) has called on Johnson & Johnson to cut the price of its anti-tuberculosis medicine Sirturo (bedaquiline), to not more than $1...
View ArticleClik here to view.
Is the US opioid litigation nearing an end game?
Drugmakers, wholesalers and lawmakers in the US are said to be thrashing out the details of a big settlement – maybe as much as $50 billion – to settle thousands of lawsuits related to the US opioid...
View ArticleClik here to view.
Lawsuit-laden J&J recalls baby powder after asbestos alert
Johnson & Johnson has said it is recalling around 33,000 bottles of baby powder in the US, after the FDA found tiny amounts of asbestos in samples taken from a bottle purchased online. The big US...
View ArticleClik here to view.
Major US retailers pull J&J’s talc from shelves over asbestos fears
A trio of major US retailers including Walmart are removing all 22-ounce bottles of Johnson & Johnson’s baby powder from their shelves after last week’s asbestos scare. CVS said on Thursday that it...
View ArticleClik here to view.
J&J refutes FDA findings on asbestos in talc
Johnson & Johnson has rejected an assertion by the FDA that asbestos had been found in one of its Baby Powder talc products, saying independent testing has found otherwise. The company claims it...
View ArticleClik here to view.
Janssen taps wearable tech in Invokana heart failure trial
Janssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world trial that will draw on smartphone and wearable tech could narrow the gap. The...
View ArticleClik here to view.
13th Annual Pharma Resource Planning and Portfolio Management
You are entitled to a $200 Discount as a reader of pharmaphorum.com! It is of high importance that the Pharma and Biotech industries are seeking new ways to strategically and continuously manage their...
View ArticleClik here to view.
FDA nod for AZ’s Calquence sets up new Imbruvica showdown
AbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from AstraZeneca, after the FDA approved rival drug Calquence. The US...
View ArticleClik here to view.
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
AstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence suggests it could be a major challenger to class leader...
View ArticleClik here to view.
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM
BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM). The Chinese biotech...
View ArticleClik here to view.
J&J to buy US biotech Taris and its bladder cancer drug device
Johnson & Johnson is to buy the privately-owned biotech Taris, and a device that can deliver cancer drugs to the bladder. J&J has not announced financial details, but the company’s lead...
View ArticleClik here to view.
FDA knocks back ViiV, J&J’s long-acting HIV regimen
People with HIV hoping to be freed from daily doses of tablets will have to wait a little longer, after the FDA rejected an injection – dosed every four weeks – developed by ViiV and Johnson &...
View ArticleClik here to view.
Washington State is latest to sue Janssen over opioid marketing
Washington State has become the latest to sue Johnson & Johnson over the way it marketed opioid painkillers, according to press reports. J&J supplies raw materials used to make opiates, and the...
View ArticleClik here to view.
NICE rejects J&J’s Spravato for treatment-resistant depression
The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns....
View ArticleClik here to view.
Jury trial levies $750m damages on J&J over talc and cancer
The jury in a New Jersey trial has awarded $750 million in punitive damages against Johnson & Johnson in a case brought by four people who claimed they had developed cancer after using its talc...
View Article
